Article

Aspirin for primary prevention of CVD: Are the right people using it?


 

All analytical procedures were conducted using Statistical Analysis Software (SAS Version 9.2; Cary, NC). A complete-case framework was used.

We used multivariate logistic regression for survey data (PROC SURVEYLOGISTIC; SAS Institute, Cary, NC) to examine the association between aspirin use and sociodemographic variables. Two separate analyses were conducted, one of participants for whom aspirin therapy was indicated and the other for participants for whom it was not. The outcomes were modeled dichotomously, as regular vs nonregular aspirin users, and a collinearity check was done. 21

Initially, we created univariate models to gauge the crude relationship between each variable and aspirin use. Any variable with P<.20 in its univariate association with regular aspirin use was considered for inclusion in the final multivariate regression model. In the multivariate analyses, we sequentially eliminated variables with the weakest association with aspirin use until only significant (P<.10) independent predictors remained. Appropriate weighting was applied based on survey strata and cluster structure.19

RESULTS

Of the 831 participants who met the eligibility criteria for our analysis, 268 (32%) had an aspirin indication. TABLE 1 shows the key characteristics of the analytical sample, stratified by those for whom aspirin was indicated and those for whom it was not. The sample was primarily middle-aged (mean age 52.4±0.36) and non-Hispanic white (93%). Compared with those for whom aspirin therapy was not indicated, the group with an aspirin indication was significantly older (56.9 vs 50.3) and had a significantly higher proportion of males (97% vs 19%). As expected, those for whom aspirin was indicated were also at higher risk for CHD and stroke, most notably as a result of significantly higher systolic BP (131.9 vs 121.5 mm Hg) and lower HDL cholesterol (42.5 vs 52.6 mg/dL) compared with participants without an aspirin indication.

TABLE 1

Study sample, by sociodemographic variable and aspirin indication

VariableFull sample (N=831)Aspirin indicated (n=268)Aspirin not indicated (n=563)
Mean age, y52.456.950.3
Sex, n
Male
Female

367
464

259
9

108
455
Race/ethnicity, n
White, non-Hispanic
Nonwhite/Hispanic

776
55

252
16

524
39
Marital status, n
Married/partnered
Not married or partnered

637
194

215
53

422
141
Health insurance, n
Uninsured
Insured

76
755

26
242

50
513
Education, n
≤High school
Associate’s degree ≥Bachelor’s degree

217
312
302

77
107
84

140
205
218
Employment, n
Unemployed
Student/retiree/home
Employed

98
147
586

33
52
183

65
95
403

When aspirin was indicated, use was linked to age and sex

In the group with an aspirin indication (n=268), 83 (31%) reported taking aspirin most days of the week. The initial examination of sociodemographic variables showed that age, sex, and employment status demonstrated significant univariate associations with regular aspirin use (TABLE 2). In the multivariate model, however, the odds of regular aspirin use were significantly greater among participants who were older (odds ratio [OR], 1.07; P<.001) or female (OR, 3.49; P=.021) compared with participants who were younger or male, respectively.

TABLE 2

Participants who have an aspirin indication: Association between sociodemographic variables and regular aspirin use

VariableRegular aspirin use, OR (95% CI)P value*
Age
Older vs younger

1.07 (1.04-1.11)

.001
Sex
Female vs male

3.89 (1.42-10.67)

.008
Race/ethnicity
Nonwhite/Hispanic vs white non-Hispanic

0.55 (0.09-3.47)

.526
Marital status
Not married/partnered vs married/partner

0.83 (0.36-1.95)

.678
Health insurance
Uninsured vs insured

0.86 (0.50-1.47)

.579
Education
≥Bachelor’s degree vs ≤high school
Associate’s degree/some college vs ≤high school
1.58 (0.75-3.34)
1.36 (0.74-2.49)
.234
.325
Employment
Student or retired vs employed
Unemployed vs employed

2.96 (1.74-5.03)
0.62 (0.25-1.56)

.001
.314
*Significance was defined as P<.10.
Multivariate adjusted model: 3.49 (95% CI, 1.21-10.07; P=.021).
CI, confidence interval; OR, odds ratio.

When aspirin was not indicated, age and sex still affected use

Among the 563 participants for whom aspirin therapy was not indicated, 102 (18%) reported taking aspirin regularly. Age, sex, race/ethnicity, health insurance, and employment (TABLE 3), as well as region of residence and study enrollment year, had significant univariate associations with regular aspirin use; these variables were tested for potential inclusion in the multivariate model. In the final multivariate regression model, the odds of regular aspirin use were significantly greater among participants who were older (OR, 1.07; P<.001) and significantly lower among participants who were Hispanic or nonwhite (OR, 0.32; P=.063).

TABLE 3

Participants who do not have an aspirin indication: Association between sociodemographic variables and regular aspirin use

VariableRegular aspirin use, OR (95% CI)P value*
Age
Older vs younger

1.07 (1.04-1.10)

.001
Sex
Female vs male

1.60 (0.84-3.04)

.152
Race/ethnicity
Nonwhite or Hispanic vs white non-Hispanic

0.23 (0.07- 0.73)

.013
Marital status
Not married/partnered vs married/partnered

1.00 (0.63-1.59)

.992
Health insurance
Uninsured vs insured

0.36 (0.11- 1.15)

.086
Education
Bachelor’s or higher vs high school or less
Associate’s/some college vs high school or less
0.74 (0.35-1.57)
0.67 (0.38-1.17)
.431
.158
Employment
Student/retired vs employed
Unemployed vs employed

2.35 (1.32-4.20)
0.78 (0.26- 2.34)

.004
.652
*Significance was defined as P<.10.
Multivariate adjusted model: 0.32 (95% CI, 0.10-1.06; P=.063).
CI, confidence interval; OR, odds ratio.

Pages

Recommended Reading

Policy statement outlines components of successful stroke care
MDedge Family Medicine
PCI in noninfarct coronaries helps STEMI patients
MDedge Family Medicine
Prasugrel pretreatment ups bleeding risk in NSTE ACS
MDedge Family Medicine
TASTE: Thrombus aspiration has no mortality benefit in STEMI
MDedge Family Medicine
Saxagliptin, alogliptin show cardiovascular safety in randomized trials
MDedge Family Medicine
High-dose, high-potency statins reduced dementia risk
MDedge Family Medicine
Aliskiren fails to fight coronary atherosclerosis
MDedge Family Medicine
Edoxaban pivotal trial shows VTE efficacy, safety
MDedge Family Medicine
Undetected silent AF is present in 3% of 75-year-olds
MDedge Family Medicine
Cardiovascular ‘polypill’ improved medication adherence, hypertension
MDedge Family Medicine